Matinas BioPharma Holdings, Inc. (MTNB)
Stock Price:
$0.830 USD
-0.022 (-2.58%)
Updated Oct 30, 2020 11:58 AM EDT - Market open
Key Info
| Market Cap |
165.21M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-21.38M |
| Shares Out |
198.95M |
| EPS (ttm) |
-0.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$0.830 |
| Previous Close |
$0.852 |
| Change ($) |
-0.022 |
| Change (%) |
-2.58% |
| Day's Open |
0.850 |
| Day's Range |
0.829 - 0.885 |
| Day's Volume |
726,280 |
| 52-Week Range |
0.490 - 2.490 |
More Stats
| Market Cap |
165.21M |
| Enterprise Value |
101.04M |
| Earnings Date (est) |
Nov 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
198.95M |
| Float |
172.29M |
| EPS (basic) |
-0.13 |
| EPS (diluted) |
-0.12 |
| FCF / Share |
-0.09 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
16.52M |
| Short Ratio |
11.70 |
| Short % of Float |
9.59% |
| Beta |
2.75 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.49 |
| Revenue |
n/a |
| Operating Income |
-22.41M |
| Net Income |
-21.38M |
| Free Cash Flow |
-16.88M |
| Net Cash |
64.17M |
| Net Cash / Share |
0.32 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-22.00% |
| ROE |
-36.44% |
| ROIC |
-49.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$3.38*
(307.03% upside)
Low
1.80
Current: $0.830
High
5.00
Target: 3.38
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -19.01 | -14.77 | -16.65 | -8.26 | -10.11 | -10.46 | -3.71 |
| Net Income | -17.37 | -14.08 | -15.49 | -7.60 | -9.14 | -10.22 | -3.71 |
| Shares Outstanding | 145 | 98.10 | 90.48 | 57.65 | 51.48 | 32.08 | 19.00 |
| Earnings Per Share | -0.13 | -0.15 | -0.36 | -0.21 | -0.18 | -0.32 | -0.20 |
| Operating Cash Flow | -14.09 | -10.32 | -11.46 | -6.12 | -7.81 | -7.96 | -2.99 |
| Capital Expenditures | -0.41 | -0.54 | -0.94 | - | -0.08 | -0.29 | -0.09 |
| Free Cash Flow | -14.50 | -10.86 | -12.40 | -6.12 | -7.89 | -8.25 | -3.08 |
| Cash & Equivalents | 28.03 | 12.55 | 7.46 | 4.26 | 3.33 | 2.69 | 10.84 |
| Total Debt | 4.23 | 0.39 | 0.26 | 0.14 | 0.01 | 0.06 | - |
| Net Cash / Debt | 23.80 | 12.16 | 7.20 | 4.12 | 3.32 | 2.63 | 10.84 |
| Assets | 40.24 | 19.94 | 14.42 | 9.82 | 8.41 | 3.36 | 11.33 |
| Liabilities | 7.19 | 3.80 | 3.74 | 2.67 | 2.33 | 1.13 | 0.86 |
| Book Value | 33.05 | 16.14 | 10.68 | 7.15 | 6.07 | 2.23 | 10.47 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Matinas BioPharma Holdings, Inc. |
| Country |
United States |
| Employees |
21 |
| CEO |
Jerome D. Jabbour |
Stock Information
| Ticker Symbol |
MTNB |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: MTNB |
Description
Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.